- Congresses
- IMCAS Asia - June 2025
- IMCAS China - July 2025
- IMCAS World Congress - January 2026
- IMCAS Americas - March 2026
- Masterclasses
- IMCAS India - November 2025
- Congresses
- IMCAS Asia - June 2025
- IMCAS China - July 2025
- IMCAS World Congress - January 2026
- IMCAS Americas - March 2026
- Masterclasses
- IMCAS India - November 2025

IMCAS Academy

Introduction
Evaluation
Register
Program
Speakers
Gala
Plan your trip
Sponsor list
Accreditation

GO BACK

IMCAS Asia 2025
Program

Adapt the schedule of the livestreamed class/congress to your time zone

Time zone reference: (UTC+07:00) Asia, Bangkok

Time zone

Time zone:Change time zone

If you are logged in, change your default time zone in your account

NextGen Derm Awards

Room: Room 4 - Level 2
Date: Saturday 7 June 2025 at 14:00 to 16:00
Format: FOCUS SESSION > lectures covering a major topic of the congress

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
14:00	Dr Atchima SUWANCHINDA	Jury		146860
14:00	Dr Diane Irvine DUNCAN	Jury		146861
14:00	Dr Marina LANDAU	Jury		150010
14:00	Dr Hsien Li Peter PENG	Jury		150009
14:00	Prof Chee Leok GOH	Jury		150363
14:00	Prof Taro KONO	Jury		150378
14:00	Dr Atchima SUWANCHINDA	Introduction and preparation		150058
14:15	Dr Rajkiran TAKHARYA	A descriptive study on the association of thyroid dysfunction among people with alopecia areata in different age groups	View	146863
14:27	Dr Patricia Ann CABIEDES	Omalizumab treatment for refractory urticaria pigmentosa in an adult Filipino male: A case report	View	146862
14:39	Dr Chanawee DOPPHOOPHA	Effect of epilation therapy of axillary hair with Diode laser with combined wavelength of 810, 940 and 1,060 nanometers by static mode compared with dynamic mode to sweat production		146864
14:51	Dr Kanitha NIMITKUL	Ultrasound Imaging of the Superficial Musculoaponeurotic System (SMAS) in the face and neck of Asians		146865
15:03	Dr Krittaporn ARUNOPRAYOTE	Safety and Effectiveness of Nasolabial Folds Treatment Between Hyaluronic Acid Filler and Collagen Biostimulator: Systematic Review and Meta-Analysis		146866
15:15	Dr Pimthip KAMNUENGKIATTIWONG	Subdermal PDLLA injection for forehead wrinkle rejuvenation, A pilot study		146867
15:27	Dr Rosalyn KUPWIWAT	Quantitative Analysis of Microneedling Radiofrequency-Assisted Percutaneous Drug Delivery		146868
15:39	Dr Vatanya RUNGTIRAVATANANON	Efficacy and optimized dosage of botulinum toxin type A injection for acne vulgaris, enlarged pore, and oiliness: A randomized placebo-controlled trial		146869
15:51		To be continued after coffee break		146870

Go to previous session

Go to next session

Recommended sessions

Alopecia (hair loss)

Drugs

Skin diseases

Dr Atchima SUWANCHINDA

Dermatologist

Thailand

Other author(s) :

Jury

Dr Diane Irvine DUNCAN

Plastic Surgeon

United States

Other author(s) :

Jury

Dr Marina LANDAU

Dermatologist

Israel

Other author(s) :

Jury

Dr Hsien Li Peter PENG

Dermatologist

Taiwan

Other author(s) :

Jury

Prof Chee Leok GOH

Dermatologist

Singapore

Other author(s) :

Jury

Prof Taro KONO

Plastic Surgeon

Japan

Other author(s) :

Jury

Dr Atchima SUWANCHINDA

Dermatologist

Thailand

Other author(s) :

Introduction and preparation

Dr Rajkiran TAKHARYA

Dermatologist

India

Other author(s) : Dr Lisa Jeniffer Dsouza

A descriptive study on the association of thyroid dysfunction among people with alopecia areata in different age groups

Objectives: AIM AND OBJECTIVES

To find the correlation between Alopecia Areata and thyroid related disorders.
Objective –
1. To assess the severity and duration of Alopecia Areata in varied age
groups of patients visiting the dermatology OPD.
2. To determine the levels of serum T3, T4, TSH and anti-TPO antibodies
in patients with Alopecia Areata.
3. To compare the association between Alopecia Areata and thyroid
dysfunction.

Introduction: Alopecia Areata (AA) is a common hair loss condition with a lifetime
prevalence of approximately 2% that is characterized by acute onset of non-scarring
hair loss in usually sharply defined areas. The most frequent clinical presentation of AA is in the form of single or multiple patches. The characteristic patch of AA is usually round or oval and is completely bald and smooth. Occasionally, AA may progress to complete baldness, which is referred to as alopecia (areata) totalis. When the entire body suffers from complete hair loss, it is referred to as alopecia (areata) universalis.

Materials / method: Study design: Cross sectional study
Inclusion criteria –
- All consenting patients aged between 7 to 70 years with clinically diagnosed Alopecia Areata attending skin OPD were included in the study.
Patients belonging to Paediatric age group, consent from both the parents was obtained
- Both sexes were included

Exclusion criteria:
- Patients with other autoimmune disorders
- Patients on systemic steroids

Sample size: 100 participants
Sampling technique – Convenience sampling

Results: Positive family history of alopecia areata was noted in 83% cases. Atopy was noted in 60% of patients. Patchy type was the most common type of AA encountered (69%). Nail involvement was seen in 13% cases and pitting was the commonest finding. Three patients (3%) had hypothyroidism as defined by low T3 & T4 levels. None of our patients had deranged TSH levels. Anti TPO antibody positivity was observed in 43 % and anti-thyroglobulin antibody positivity was observed in 31 % of the study participants. No correlation was found between Alopecia Areata and thyroid disorder.

Conclusion: Our study found no significant association between Alopecia areata and autoimmune thyroid dysfunction. Lack of control group, small sample size and lack of long term follow up are the limitations of the present study. We suggest studies
involving large sample size with control group and with long term follow up to
determine the association between alopecia areata and thyroid dysfunction.
Our findings do not support screening for thyroid disease in Alopecia areata
patients without obvious thyroid disorder. Longer follow ups are needed to observe if patient develop clinical thyroid dysfunction.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Patricia Ann CABIEDES

Dermatologist

Philippines

Other author(s) : Patricia Ann F. Cabiedes, MD; Emmerson Gale S. Vista, MD, FPDS

Omalizumab treatment for refractory urticaria pigmentosa in an adult Filipino male: A case report

Objectives: The main objectives of this case report are to present the clinical presentation and diagnosis of Urticaria Pigmentosa, recognize the role of multidisciplinary evaluation in ruling out systemic involvement, and critically assess the variable efficacy of subcutaneous Omalizumab in refractory cases.

Introduction: INTRODUCTION: Urticaria Pigmentosa is a subtype of cutaneous mastocytosis, a rare condition characterized by an abnormal proliferation of mast cells in one or more organs. It is often linked to mutations in c-kit gene. The disease presents a clinical spectrum, ranging from mild skin manifestations to systemic involvement, particularly in adults. Omalizumab, a monoclonal antibody targeting immunoglobulin E (IgE), has shown potential in managing symptoms that are refractory to conventional treatment, with large cohort studies reporting a 76.8% overall response rate.

Materials / method: CASE REPORT: This is a case of a 40-year-old Filipino male who presented with 8 year-history of generalized tan to hyperpigmented macules and papules. Symptoms included severe pruritus and wheal formation triggered by scratching, friction, and humid weather. Baseline laboratories were normal. Skin biopsy showed numerous mast cells, with positive CD117 and Giemsa stains confirming the diagnosis of Urticaria Pigmentosa.

Results: The patient was referred to hematology and gastroenterology, where systemic involvement was ruled out. Oral antihistamines and topical mid-potent corticosteroids were initiated which halted the pruritus and progression of lesions, however, still with recurrence. The patient received two doses of subcutaneous Omalizumab (150 mg/vial) at 4-week intervals over 12 weeks with no reported adverse events. Response was monitored overtime, however, no significant improvement was reported in terms of pruritus, flare reduction or the number of lesions.

Conclusion: CONCLUSION: Urticaria Pigmentosa follows a chronic course and requires periodic monitoring. The primary treatment goal focuses on trigger avoidance and symptomatic control. A multidisciplinary approach is essential to confirm the absence of systemic involvement. Based on systematic reviews and several case studies, Omalizumab demonstrates promising results as a therapeutic option for refractory cases; however, clinical outcomes continue to vary among patients. Therefore, additional clinical trials are necessary to further evaluate its efficacy.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Chanawee DOPPHOOPHA

Dermatologist

Thailand

Other author(s) :